Oncology
Clinical Translational Research
Single Nucleotide Change in the Cannabinoid Receptor-1 (CNR1) Gene in Colorectal Cancer OutcomeBedoya F.a · Rubio J.C.a · Morales-Gutierrez C.b · Abad-Barahona A.b · Lora Pablos D.c · Meneu J.C.b · Moreno-Gonzalez E.b · Enriquez de Salamanca R.a · Vegh I.aaCentro de Investigación, bDepartment of Surgery and cUnit of Epidemiology, Hospital Universitario 12 de Octubre, Madrid, Spain
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: December 15, 2008
Accepted: January 05, 2009
Published online: May 05, 2009
Issue release date: May 2009
Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 3
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
The cannabinoid receptor-1 (CNR-1) and endogenous agonists of this receptor are present in the central and peripheral nervous systems including the gastrointestinal nervous system. The surgically rejected specimens of human colorectal cancers and paired normal tissues were studied to detect mutations in the CNR1 gene by sequencing method. The results were compared to clinicopathological parameters and correlated with overall survival time. Sixty-three colorectal cancer patients, who underwent surgical excision of colorectal carcinoma, were included in this study. The coding region of the CNR1 gene was studied: a nucleotide change (G→A) at position 1359 was identified by direct sequencing of PCR. Thirty-eight patients had the G/G genotype (wild type) in tumor areas and 25 patients had G/A heterozygous or A/A homozygous genotype. Univariate analysis revealed 2 independent variables associated with CNR1 gene mutation. The results show that the patients with Dukes stage C and D had a 2.9 times (p = 0.04) and patients that were lymph node positive had 2.8 times (p = 0.05) greater probability of nucleotide change in CNR1 gene. Genotype G/A plus A/A had a shorter overall survival time than G/G wild-type patients (p < 0.05). Indeed nontumor paired colorectal tissues showed nucleotide change. A large number of patients with mutation in the CNR1 gene were observed. These preliminary findings highlight the importance of further studies in the use of cannabinoid analogs as receptor ligands to analyze potential therapeutic effects.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR: Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002;66:307–344.
- Massa F, Storr M, Lutz B: The endocannabinoid system in the physiology and pathophysiology of the intestinal tract. J Mol Med 2005;83:944–954.
-
Darmani NA: Δ9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001;24:189–203.
External Resources
-
Di Marzo V, Izzo AA: Endocannabinoid overactivity and intestinal inflammation. Gut 2007;55:1373–1376.
External Resources
- Ligresti A, Bisogno T, Matias I, De-Petrocellis L, Cascio MG, Cosenza V, D’Argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677–687.
- 6- Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, Di Marzo V: Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008;86:89–98.
- Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA: Antineoplasic activity of cannabinoids. J Natl Cancer Inst 1975;55:597–602.
- Bifulco M, Di Marzo V: Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547–550.
-
Spindler KLG, Nielsen JN, Ornskov D, Brandslund I, Jakobsen A: Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol 2007;17:1–5.
-
Cheirsilpa A, Ruangvejvorachai P, Karalak A, Sangprakarn S, Pummai S, Sangrajrang S: Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Cancer Ther 2007;5:137–142.
-
Gonzalez JF, Vicioso L, Alvarez M, Sevilla I, Marques E, Gallego E, Alonso L, Matilla A, Alba E: Association between VEGF expression in tumor-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. Cancer Biomarkers 2007;3:325–333.
External Resources
- Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH: Vascular endothelial growth factor gene polymorphism associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62–66.
- Morales-Gutierrez C, Vegh I, Colina F, Gomez-Cámara A, Garcia CA, Landa JI, Ballesteros D, Carreira PE, Enriquez-de-Salamanca R: Survival of patients with colorectal carcinoma. Cancer 1999;86:1675–1681.
- Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O’Connell MJ, Witzing TE, Farr GH Jr, Goldberg RM, Tribodeau SN: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295–1303.
- Vegh I, De-la-Cruz J, Navarro S, Morales C, Colina F, Abad A, De-la-Calle A, Enriquez-de-Salamanca R, Moreno-Gonzalez E: Colorectal cancer relapse allelic alterations associated with tumour marker overexpression. Oncology 2003;65:146–151.
- Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA: Genetic tumor markers with prognostic impact in Dukes’ stage B and C colorectal cancer. J Clin Oncol 2003;21:820–829.
- Han HS, Park Y-M, Hwang TS: Differential expression of Bcl-2, Bcl-Xl and p53 in colorectal cancer. J Gastroenterol Hepathol 2006;21:1108–1114.
-
Jass JR, Sobin LH: Histological Typing of Intestinal Tumours, ed 2. Berlin, Springer-Verlag, 1989.
-
Sobin LH, Wittekind CH, Akerley W: TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002.
- Gadzicki D, Müller-Vahl K, Stuhrmann M: A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999;13:321–323.
-
Fogli S, Breschi MC: The molecular bases of cannabinoid action in cancer.. Cancer Ther 2008;6:103–145.
External Resources
- Joseph J, Niggermann B, Zaenker KS, Entschladen F: Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004;53:723–728.
- Scorticati C, Mohn C, De Laurentis A, Vissio P, Fernandez Solari J, Seilicovich A, McCann SM, Rettori V: The effect of anandamide on prolactin secretion is modulated by estrogen. Proc Natl Acad Sci USA 2003;100:2134–2139.
- Scorticati C, Fernández-Solari J, De Laurentis A, Mohn C, Prestifilippo JP, Lasaga M, Seilicovich A, Billi S, Franchi A, McCann SM, Rettori V: The inhibitory effect of anandaminde on luteinizing-hormone-realizing hormone secretion is reversed by estrogen. Proc Natl Acad Sci USA 2004;101:11891–11896.
- Wenger T, Tóth BE, Martin BR: Effect of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci 1995;56:2057–2063.
- Weindenfeld J, Feldman S, Mechoulam R: Effect of brain constituent, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis. Neuroendocrinology 1994;59:110–112.
- Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, Fan W, Li Q, Wang Q, Zhong D, Miao X: Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006;171:31–38.
Article / Publication Details
Received: December 15, 2008
Accepted: January 05, 2009
Published online: May 05, 2009
Issue release date: May 2009
Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 3
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
